LEADER 03179nam  22006854a 450 
001 9910808730803321
005 20200520144314.0
010   $a1-107-13115-4
010   $a1-280-15491-8
010   $a9786610154913
010   $a0-511-11971-2
010   $a0-511-04173-X
010   $a0-511-14836-4
010   $a0-511-33030-8
010   $a0-511-54394-8
010   $a0-511-04410-0
035   $a(CKB)1000000000006029
035   $a(EBL)202068
035   $a(OCoLC)70731046
035   $a(SSID)ssj0000220628
035   $a(PQKBManifestationID)11191268
035   $a(PQKBTitleCode)TC0000220628
035   $a(PQKBWorkID)10143957
035   $a(PQKB)10425488
035   $a(UkCbUP)CR9780511543944
035   $a(MiAaPQ)EBC202068
035   $a(Au-PeEL)EBL202068
035   $a(CaPaEBR)ebr10062683
035   $a(CaONFJC)MIL15491
035   $a(PPN)26133347X
035   $a(EXLCZ)991000000000006029
100   $a20010924d2002      uy         0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aPharmacogenetics of psychotropic drugs /$fedited by Bernard Lerer
205   $a1st ed.
210   $aCambridge, UK ;$aNew York $cCambridge University Press$d2002
215   $a1 online resource (x, 446 pages) $cdigital, PDF file(s)
300   $aTitle from publisher's bibliographic system (viewed on 05 Oct 2015).
311   $a0-521-18961-6 
311   $a0-521-80617-8 
320   $aIncludes bibliographical references and index.
327   $aCover; Half-title; Title; Copyright; Contents; Contributors; Part I Introduction; Part II Clinical background and research design; Part III Molecular background; Part IV Pharmacokinetics; Part V Specific psychotropic drugs and disorders; Part VI Pharmacogenetics and brain imaging; Part VII Industrial perspectives; Index
330   $aPharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
606   $aPsychotropic drugs
606   $aPharmacogenetics
615  0$aPsychotropic drugs.
615  0$aPharmacogenetics.
676   $a615/.788
701   $aLerer$b Bernard$01761359
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910808730803321
996   $aPharmacogenetics of psychotropic drugs$94200774
997   $aUNINA